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ABSTRACT
 
Needs-based instruments have been developed for a wide
range of diseases. Recently, they have been applied widely
in dermatology. This paper describes these applications
and shows how they have proved of value.
Keywords: clinical meaningfulness, PIQoL-AD,
PSORIQoL, QoLIAD, RGHQoL.
 
Atopic Dermatitis
 
PIQoL-AD
 
Clinical trials.
 
The Parents’ Index of Quality of
Life in Atopic Dermatitis (PIQoL-AD) has been
employed as an outcome measure in several clinical
trials [1]. It was included in two 26-week pediatric
atopic dermatitis (AD) trials with identical designs
conducted in the US [2]. These were designed to
evaluate the efﬁcacy and safety of pimecrolimus
(Elidel®, SDZ ASM 981; Novartis Pharmaceuticals,
East Hanover, NJ, USA) cream 1%. A secondary
aim of both trials was to evaluate the QoL impact of
pimecrolimus compared with its vehicle. Patients
were randomized to receive either pimecrolimus or
vehicle for 6 weeks after which all participants
received the active treatment for a further 20 weeks.
PIQoL-AD scores were available for 241 cases at
baseline (158-pimecrolimus, 83-vehicle), 193 at
6 weeks (132 pimecrolimus, 61 vehicle), and 161 at
6 months (113-pimecrolimus, 48-vehicle). Improve-
ment in parents’ QoL was seen for both groups
between baseline and 6 weeks (
 
P
 
 
 
<
 
 0.001 pime-
crolimus, 
 
P
 
 
 
<
 
 0.05 vehicle) and 6 months (
 
P
 
 
 
<
 
 0.001
both groups). Analysis of covariance conducted on
PIQoL-AD scores at 6 weeks showed statistically
signiﬁcant superiority of pimecrolimus compared
with vehicle (
 
P
 
 
 
<
 
 0.05). These trials indicated that
the PIQoL-AD is sensitive to changes in QoL in the
parents of children being treated for AD and its
expediency for use in clinical trials was conﬁrmed.
PIQoL-AD data are also available from two 12-
month international clinical trials evaluating the
efﬁcacy and safety of pimecrolimus in the long term
treatment of pediatric AD [3,4]. Both trials were
randomized and double-blinded and compared two
treatment strategies, one involving the use of emol-
lients, pimecrolimus, and topical corticosteroids,
the other “usual care,” emollients plus topical cor-
ticosteroids, with a vehicle cream to maintain study
blinding. Trial A involved infants aged between
3 months and 2 years, while trial B included chil-
dren aged 2 to 17 years. QoL assessments were
conducted at baseline, 6 weeks, 6 months, and
12 months.
PIQoL-AD scores were available for 154 cases in
trial A (126 pimecrolimus, 28 usual care) and 231
cases in trial B (157 pimecrolimus, 74 usual care).
Generalized linear modelling of PIQoL-AD scores
at each postbaseline visit showed a greater impact
on QoL for pimecrolimus compared with control at
all time points in both trials, conﬁrming ﬁndings
from the earlier shorter term trials.
 
Clinical meaning of PIQoL-AD scores.
 
Data from
clinical trials in which the PIQoL-AD was employed
were analyzed to examine the clinical meaning of
PIQoL-AD scores [5]. These secondary analyses
were aimed at gaining a clearer understanding of
the underlying meaning of PIQoL-AD absolute and
change scores.
An anchor-based method of determining clinical
signiﬁcance was employed. PIQoL-AD scores were
anchored to four AD severity indicators (the
Eczema Area Severity Index (EASI [6]); the Investi-
gator’s Global Assessment (IGA), Pruritus Severity
(PRU), and Subject’s Assessment of how well the
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AD is controlled (SA)). Data (from at least 3 time-
points) were evaluated from the 4 clinical trials of
pimecrolimus cream 1% involving 1393 children
with AD. Low levels of correlation (0.38–0.44)
were observed between PIQoL-AD scores and the
severity indicators, conﬁrming previous ﬁndings in
dermatological studies [7–9].
Data for all time-points in all trials were com-
bined and PIQoL-AD mean, median, standard devi-
ation, and 95% conﬁdence interval scores were
calculated for each of the severity levels in the
anchor measures. The results showed a clear pro-
gression in mean PIQoL-AD scores with increasing
severity of AD according to the IGA, PRU, SA, and
EASI measures. There was an absence of overlap of
the 95% conﬁdence levels in most cases. Statistical
tests indicated that PIQoL-AD scores varied by
levels on all four anchor measures at 
 
P
 
 
 
<
 
 0.001.
The analyses give an indication of what the
PIQoL-AD absolute and change scores mean in
terms of the severity indicators. For example, the
parent of a child rated as IGA category 3 (moderate
disease) would be expected to score between 8.4
and 9.4 on the PIQoL-AD. The largest mean
PIQoL-AD change score between any two consecu-
tive severity levels for any of the 4 clinical measures
is 3.1, which represents a reduction in pruritus from
3 (severe) to 2 (moderate).
The results also suggested that the relations
between disease severity and QoL are not necessar-
ily linear. For example, improving the severity of
pruritus from 3 to 2 would produce a greater
improvement in QoL than an improvement in pru-
ritus from 1 to 0 (Fig. 1).
 
Discriminative ability. 
 
The application of the
PIQoL-AD to parents of children with AD showed
that the QoL of the parent is related to the location
of AD lesions [1]. Parents whose children had AD
on their hands or face had worse QoL than those
whose children did not. Although the observed dif-
ferences reached statistical signiﬁcance (
 
P
 
 
 
<
 
 0.05) in
the UK and Germany only, the number of children
who were not affected on their hands or face was
relatively small in most countries (see Fig. 2).
The PIQoL-AD was also able to show differences
at the 99% signiﬁcance level between severity
groups (mild, moderate, quite/very severe) in all
countries, with scores deteriorating with increased
severity of the child’s AD.
 
QoLIAD
 
Application  of  the  QoLIAD.
 
The international
application of the Quality of Life Index for Atopic
Dermatitis (QoLIAD [10]) designed for use with
adults also found that QoL was dependent on the
location of AD lesions. Higher QoLIAD scores,
indicating worse QoL, were observed for those
whose face or hands were affected (Fig. 3) with
these differences reaching statistical signiﬁcance in
the UK, France, and Germany. In contrast, the Psy-
chological General Well-Being Scale [11] failed to
show differences associated with location of lesions
in this or the PIQoL-AD validation study reported
above.
 
Figure 1
 
Mean PIQoL-AD score and conﬁdence intervals by PRU
category.
 
Figure 2
 
PIQoL-AD scores by geography of  child’s AD. UK, United
Kingdom; NL, Netherlands; F, France; D, Germany; US, United States.
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To date the QoLIAD has only been used in a
trial in Germany [12]. The study involved 192
patients with mild-to-severe AD who were rand-
omized to receive either pimecrolimus cream 1%
or vehicle cream for 24 weeks. Statistically, a sig-
niﬁcantly greater improvement (
 
P
 
 
 
=
 
 0.002) was
observed for patients in the pimecrolimus group
than for those in the control group. In the two
groups, the QoLIAD scores improved by 25.6%
and 7.4%, respectively.
 
Psoriasis
 
PSORIQoL and PSAQoL
 
Application of PSORIQoL and PSAQoL.
 
As with
the PIQoL-AD and QoLIAD, scores on the UK and
US versions of the Psoriasis Index of Quality of Life
(PSORIQoL [13]) were also related to whether or
not patients had lesions on their face and/or hands.
In contrast, Psoriatic Arthritis Quality of Life
(PsAQoL [14]) scores were unrelated to whether or
not facial skin was affected. However, patients
whose hands were affected by psoriasis scored sig-
niﬁcantly worse than those whose hands were not
affected (
 
P <
 
 0.001).
It is signiﬁcant that it was consistently found that
the visibility of dermatological disease is important
in determining the QoL of the affected patient.
Severity indicators such as the EASI and PASI scores
do not take this factor into account, possibly reduc-
ing the level of association between severity and
QoL measures.
The recently developed PSORIQoL has only been
employed in a small-scale trial with patients. The
measure is currently being adapted for use in a
number of European languages and French- and
English-Canadian versions are also being
developed.
 
Recurrent Genital Herpes
 
RGHQoL
 
Application of RGHQoL.
 
In a study by Patel and
colleagues [15], the Recurrent Genital Herpes
Quality of Life instrument (RGHQoL [16]) was
employed to assess the impact of suppressive anti-
viral therapy on the QoL of 1349 patients with
recurrent genital herpes (RGH). Mean RGHQoL
change scores were signiﬁcantly (P < 0.05) greater
from baseline to 3, 6, and 12 months in the treat-
ment groups (valaciclovir and acyclovir) than in the
placebo group. Retrospective analysis also indicated
that, at baseline, patients who had experienced
more than 10 RGH outbreaks in a year had much
poorer QoL than patients who experienced fewer
outbreaks. The study conﬁrmed the sensitivity of
the RGHQoL to changes in QoL associated with
active treatment.
In a later study [17], the RGHQoL was used
together with the SF-36 to gauge perceptions of 298
patients about the burden of RGH. The RGHQoL
was able to discriminate between patients who var-
ied according to the frequency of RGH outbreaks,
with those experiencing fewer outbreaks obtaining
signiﬁcantly (P < 0.002) better RGHQoL scores. In
contrast, SF-36 scores did not vary with outbreak
frequency.
Other  research  with  the  RGHQoL. It has been
shown that both relative and absolute utility values
can be elicited from RGH patients’ preferences for
situations derived from RGHQoL items [18]. This
represents the ﬁrst work undertaken to derive utility
values from a disease-speciﬁc QoL instrument.
Using conjoint analysis for the derivation of relative
utility and time trade-off and ranking exercises for
absolute utility derivation, it was shown that utility
values could be elicited suitable for use in QALY-
type analyses.
 
Summary
 
This paper has outlined instances of the application
of needs-based QoL instruments in dermatology.
 
Figure 3
 
QoLIAD scores by location of  AD lesions. UK, United King-
dom; NL, Netherlands; F, France; D, Germany; US, United States.
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Use of measures speciﬁc to atopic dermatitis (pedi-
atric and adult), psoriasis, psoriatic arthritis, and
recurrent genital herpes have been described. The
measures have been applied in both clinical trials
and nonclinical investigative studies. It is hoped that
studies of the clinical meaning of QoL instruments
(such as that of the PIQoL-AD) which helps relate
QoL to measures of disease severity will encourage
greater use of QoL instruments in dermatological
research.
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